Timing of Immune-Related Adverse Events with Relation to IL-2 Treatment
| irAEs/Total Patients (%) | Prior to IL-2 | During IL-2 | After IL-2 | |
|---|---|---|---|---|
| Total | 152/1535 (8.4%) | 31 | 24 | 97 |
| mM | 99/623 (16%) | 16 | 12 | 71 |
| mRCC | 53/920 (5.8%) | 15 | 12 | 26 |
| Total irAEs | 31 | 24 | 97 | |
| Related to IL-2 | NA | During and after IL-2 | 74 | |
| Undetermined if Related to IL2 or CPI | NA | 15 | ||
| Related to CPI | NA | 24 |
mM metastatic melanoma, mRCC metastatic renal cell cancer, irAEs immune-related adverse events, IL-2 interleukin-2, CPI checkpoint inhibitor, NA - not applicable